142 related articles for article (PubMed ID: 35964428)
21. Water-Soluble Combretastatin A4 Phosphate Orally Delivered via Composite Nanoparticles With Improved Inhibition Effect Toward S180 Tumors.
Shen Y; Wu L; Qiu L
J Pharm Sci; 2017 Oct; 106(10):3076-3083. PubMed ID: 28619603
[TBL] [Abstract][Full Text] [Related]
22. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer.
Ng QS; Goh V; Carnell D; Meer K; Padhani AR; Saunders MI; Hoskin PJ
Int J Radiat Oncol Biol Phys; 2007 Apr; 67(5):1375-80. PubMed ID: 17275203
[TBL] [Abstract][Full Text] [Related]
23. Development Of Novel Liposome-Encapsulated Combretastatin A4 Acylated Derivatives: Prodrug Approach For Improving Antitumor Efficacy.
Gu Y; Ma J; Fu Z; Xu Y; Gao B; Yao J; Xu W; Chu K; Chen J
Int J Nanomedicine; 2019; 14():8805-8818. PubMed ID: 31806973
[TBL] [Abstract][Full Text] [Related]
24. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
25. Enhancing intratumoral biodistribution and antitumor activity of nab-paclitaxel through combination with a vascular disrupting agent, combretastatin A-4-phosphate.
Gao M; Zhang D; Yao N; Jin Q; Jiang C; Zhang J; Wang F
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1187-1194. PubMed ID: 31520101
[TBL] [Abstract][Full Text] [Related]
26. Covalent functionalization of SWCNT with combretastatin A4 for cancer therapy.
Assali M; Zaid AN; Kittana N; Hamad D; Amer J
Nanotechnology; 2018 Jun; 29(24):245101. PubMed ID: 29583132
[TBL] [Abstract][Full Text] [Related]
27. Concentration-Induced J-Aggregate Formation Causes a Biphasic Change in the Release of trans-Combretastatin A4 Disodium Phosphate from Archaeosomes and the Subsequent Cytotoxicity on Mammary Cancer Cells.
Daswani VP; Ayesa U; Venegas B; Chong PL
Mol Pharm; 2015 Oct; 12(10):3724-34. PubMed ID: 26355665
[TBL] [Abstract][Full Text] [Related]
28. Nanoparticles Composed of PEGylated Alternating Copolymer-Combretastatin A4 Conjugate for Cancer Therapy.
Zhang Y; Liu X; Wang X; He P; Xiao C; Yu H; Chen X
Macromol Biosci; 2021 Aug; 21(8):e2100077. PubMed ID: 34031970
[TBL] [Abstract][Full Text] [Related]
29. Targeting tumour vasculature: the development of combretastatin A4.
Griggs J; Metcalfe JC; Hesketh R
Lancet Oncol; 2001 Feb; 2(2):82-7. PubMed ID: 11905799
[TBL] [Abstract][Full Text] [Related]
30. p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4.
Quan H; Xu Y; Lou L
Int J Cancer; 2008 Apr; 122(8):1730-7. PubMed ID: 18074350
[TBL] [Abstract][Full Text] [Related]
31. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.
Rustin GJ; Galbraith SM; Anderson H; Stratford M; Folkes LK; Sena L; Gumbrell L; Price PM
J Clin Oncol; 2003 Aug; 21(15):2815-22. PubMed ID: 12807934
[TBL] [Abstract][Full Text] [Related]
32. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging.
Galbraith SM; Maxwell RJ; Lodge MA; Tozer GM; Wilson J; Taylor NJ; Stirling JJ; Sena L; Padhani AR; Rustin GJ
J Clin Oncol; 2003 Aug; 21(15):2831-42. PubMed ID: 12807936
[TBL] [Abstract][Full Text] [Related]
33. Pegylated liposomal encapsulation improves the antitumor efficacy of combretastatin A4 in murine 4T1 triple-negative breast cancer model.
Mirzavi F; Barati M; Vakili-Ghartavol R; Roshan MK; Mashreghi M; Soukhtanloo M; Jaafari MR
Int J Pharm; 2022 Feb; 613():121396. PubMed ID: 34942328
[TBL] [Abstract][Full Text] [Related]
34. The vascular-disrupting agent, combretastatin-A4-phosphate, enhances neurogenic vasoconstriction in rat small arteries.
Su J; Laursen BE; Eskildsen-Helmond Y; Horsman MR; Simonsen U
Eur J Pharmacol; 2012 Nov; 695(1-3):104-11. PubMed ID: 22981665
[TBL] [Abstract][Full Text] [Related]
35. Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status.
Jaroch K; Karolak M; Górski P; Jaroch A; Krajewski A; Ilnicka A; Sloderbach A; Stefański T; Sobiak S
Pharmacol Rep; 2016 Dec; 68(6):1266-1275. PubMed ID: 27686966
[TBL] [Abstract][Full Text] [Related]
36. Thermo-sensitive polypeptide hydrogel for locally sequential delivery of two-pronged antitumor drugs.
Wei L; Chen J; Zhao S; Ding J; Chen X
Acta Biomater; 2017 Aug; 58():44-53. PubMed ID: 28576715
[TBL] [Abstract][Full Text] [Related]
37. The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors.
Deng C; Zhao J; Zhou S; Dong J; Cao J; Gao J; Bai Y; Deng H
Mol Ther; 2020 Jan; 28(1):75-88. PubMed ID: 31672285
[TBL] [Abstract][Full Text] [Related]
38. Multifunctional dendrimer/combretastatin A4 inclusion complexes enable in vitro targeted cancer therapy.
Zhang M; Guo R; Wang Y; Cao X; Shen M; Shi X
Int J Nanomedicine; 2011; 6():2337-49. PubMed ID: 22072871
[TBL] [Abstract][Full Text] [Related]
39. Combretastatin A4 phosphate induces programmed cell death in vascular endothelial cells.
Ding X; Zhang Z; Li S; Wang A
Oncol Res; 2011; 19(7):303-9. PubMed ID: 21936400
[TBL] [Abstract][Full Text] [Related]
40. Development of a rapid and sensitive LC-MS/MS assay for the determination of combretastatin A4 phosphate, combretastatin A4 and combretastatin A4 glucuronide in beagle dog plasma and its application to a pharmacokinetic study.
Wang X; Chen Z; Che J; Meng Q; Shan C; Hou Y; Liu X; Chai Y; Cheng Y
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Nov; 877(30):3813-21. PubMed ID: 19822461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]